Certoparin sodium
Pharmaceutical drug
- none
- DB09261
- none
- DTXSID301010914
Certoparin (trade names Sandoparin, Embolex) is an antithrombotic medication. It is a low molecular weight heparin, primarily active against factor Xa. Like other low molecular weight heparins, it is used to prevent deep venous thrombosis.[1]
References
- ^ Donadini MP, Ageno W, Guasti L, Squizzato A (July 2013). "Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies". Expert Opinion on Drug Metabolism & Toxicology. 9 (7): 901–9. doi:10.1517/17425255.2013.794787. PMID 23621639. S2CID 31020741.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
| Glycoprotein IIb/IIIa inhibitors |
|
|---|---|
| ADP receptor/P2Y12 inhibitors | |
| Prostaglandin analogue (PGI2) | |
| COX inhibitors | |
| Thromboxane inhibitors | |
| Phosphodiesterase inhibitors | |
| Other |
| Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
|---|---|---|---|---|---|
| Factor Xa inhibitors (with some II inhibition) |
| ||||
| Direct thrombin (IIa) inhibitors |
| ||||
| Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
